Jan 19, 2026
August 28, 2025
Akeso Eyecare has successfully completed the first commercial delivery of the world’s first Triple-Effect Lithography Myopia Management Lenses, marking a major milestone in the evolution of precision-driven myopia control.
Built on Akeso’s proprietary MetaRx™ lens lithography technology, the Spark Crystal Triple-Effect Myopia Management Lens has entered real-world application, with nearly 7,000 lenses delivered in the initial production batch.
This achievement demonstrates not only technological leadership, but also scalable manufacturing readiness—a critical step in bringing high-precision myopia management from innovation to widespread clinical use.
The Spark Crystal Lens is the first myopia management lens to integrate nano-scale lithographic processing, compound optical design, and high–refractive-index materials within a single system.
This triple-layered engineering approach is designed to systematically address persistent challenges in adolescent myopia management, including:
By combining optical precision, material science, and structural consistency, the lens delivers a new standard for both clinical performance and everyday usability.
As the world’s first myopia management lens built on Triple-Effect Compound Optical Design with lithographically defined microstructures, the Spark Crystal Lens introduces multiple engineering breakthroughs.
Using ultra-precision lithographic processes adapted from advanced industrial manufacturing, MetaRx™ technology enables exceptional control over micro-optical structures. This significantly improves the consistency, repeatability, and stability of optical performance, overcoming the inherent precision limits of conventional lens fabrication.
The lens integrates multiple functional optical effects within a single structure, enabling high-efficiency defocus, pupil-matched optical zones, and personalized tolerance coverage—without compromising comfort.
Together, these features ensure daily wearing safety, visual quality, and long-term comfort, which are critical for pediatric and adolescent users.
The successful delivery of the first batch validates Akeso’s strategy of redefining myopia management lenses through lithography-based precision manufacturing. More importantly, it confirms that such advanced optical designs can be produced at scale with reliable quality control.
This milestone provides the global eyewear industry with a practical, implementable pathway toward next-generation, high-precision myopia control solutions.
Akeso will continue to expand the research, development, and clinical application of lithographic lens technologies, driving further innovation across myopia prevention, control, and visual health management.
By combining precision optics, AI-driven personalization, and scalable manufacturing, Akeso remains committed to delivering reliable, evidence-based solutions that support the long-term visual health of children and adolescents worldwide.
Akeso Eyecare is a doctor-founded eye-technology company and CDMO focused on improving vision care. We design and build advanced solutions like AR displays for myopia prevention, eye tracking, extended reality devices, and digital vision health tools used in eye care and smart technology.
Our mission is to improve global vision health through smart innovation. By combining optical design, materials science, and AI, our R&D team supports partners from early research to custom design, manufacturing, and large-scale production, always guided by medical expertise, collaboration, sustainability, and patient-first thinking.
Akeso – engineering the future of vision.
Engineering the
Future of Vision.